Epidemiological analysis of cytogenetic abnormalities in patients with newly-diagnosed multiple myeloma: a multi-center retrospective study

Ruifeng Yuan; Yujun Dong; Chunrui LI; Wenrong Huang; Limo Zhang; Qiang Zhu; Li XU; Yanjie XU; Qian XU; Guangxun Gao; Fengyan Jin

Return

Epidemiological analysis of cytogenetic abnormalities in patients with newly-diagnosed multiple myeloma: a multi-center retrospective study

VernacularTitle: 初治多发性骨髓瘤患者细胞遗传学异常流行病学的多中心回顾性研究
Author: Ruifeng YUAN ¹ ; Yujun DONG ² ; Chunrui LI ³ ; Wenrong HUANG ⁴ ; Limo ZHANG ⁵ ; Qiang ZHU ² ; Li XU ¹ ; Yanjie XU ³ ; Qian XU ³ ; Guangxun GAO ¹ ; Fengyan JIN ⁵
Author Information

1. Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xian 710032, China
2. Department of Hematology, Peking University First Hospital, Beijing 100034, China
3. Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
4. Department of Hematology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
5. Department of Hematology, The First Hospital of Jilin University, Changchun 130012, China
Publication Type:Journal Article
Keywords: Multiple myeloma; Cytogenetic abnormality; Epidemiology; High risk; Double-hit
From: Chinese Journal of Hematology 2020;41(1):10-15
CountryChina
Language:Chinese
Abstract: Objective:To analyze the frequency and composition of risk-related cytogenetic abnormalities (CAs) in patients with newly-diagnosed multiple myeloma (NDMM) .
Methods:The frequency and composition of risk-related CAs from a cohort of 1 015 Chinese patients with NDMM were determined by interphase fluorescence in situ hybridization (iFISH) , individually or in combination.
Results:Of the cohort of 1 015 Chinese patients with NDMM, the frequencies of IgH arrangement, del (13q) /13q14, 1q gain and del (17p) were 54.0%, 46.4%, 46.1% (35.8% and 12. 7% for 3 or more than 3 copies) and 9.9%, respectively. Among 454 patients who had the baseline information for all risk-related CAs [except t (14;20) , which was not covered by the FISH panels performed routinely at all five centers], the frequencies of t (4;14) , t (11;14) or t (14;20) were 14.1%, 11.2% and 4.8%, respectively; of them, 44.3% patients carried 2 or more CAs (28.0%, 13.4% and 2.9% for 2, 3 or ≥4 CAs) ; 83.3%, 95.0% or 68.6% patients with 1q gain, del (17p) or IgH rearrangement had 1 or more additional CA (s) , with del (13q) /13q14 as the most frequently accompanied CA; 57.7% patients carried at least 1 HRCA; the incidences of double-hit (DH) MM (DHMM) (=2 HRCAs) and triple-hit (TH) (THMM) (≥3 HRCAs) were 14.3% and 2.9%, respectively.
Conclusions:Our results provided an up-to-date profile of CAs in Chinese NDMM patients, which revealed that approximately 58% patients might carry at least 1 HRCA, and 17% could experience so-called DHMM or THMM who presumably had the worst outcome.